Company intelligence / Profile preview

GH Research PLC

Ownership: Public · GHRS
Development stage: Phase 2

Overview

In Phase 2b trial for GH001 in TRD, the primary endpoint was met with a MADRS reduction from baseline of -15.5 points compared with placebo on Day 8 (p<0.0001). The 40 patients who received GH001 saw an average 15.2 point reduction on the Montgomery-Åsberg Depression Rating Scale at Day 8, compared to an increase of 0.3 points among the 41 patients who received placebo. In the open-label extension portion of the trial, GH001 led to a 77.8% remission rate at six months in patients who completed this section.[4][6][7]

Therapeutic areas: Psychiatry
Modalities: Mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) formulations (inhalable, injectable, intranasal)
Industry: Biotech

Drug pipeline

3 assets

mebufotenin

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $1.9B
Total revenue: $0
Enterprise value: $1.5B

Beyond the preview

Go deeper on GH Research PLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GH Research PLC.

Explore the full profile